.jpg?format=webp&quality=80&width=3840)
The TRAVERSE trial, a comprehensive study on testosterone replacement therapy, found that over two years, testosterone supplementation did not increase the risk of major adverse cardiac events in older men with hypogonadism and high cardiovascular risk. While the primary safety endpoint showed no significant difference between the testosterone and placebo groups, there were slightly higher incidences of pulmonary embolism, arrhythmias, atrial fibrillation, and acute kidney injury in the testosterone group.
Like
Save
Share